Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Wow its been a strong beginning to 2018 for BSEM
insert-text-here
New Video for BSEM: https://vimeo.com/250710419
$BSEM BioStem Technologies Inc. (OTC PINK: BSEM) Announces Audit Process and Uplisting Plans to the OTCQX Market
Source: Marketwired
OAKLAND PARK, FL-(Marketwired - Apr 6, 2017) - BioStem Technologies Inc. (OTC PINK: BSEM) ("BioStem Tech" or the "Company"), an emerging International Biotechnology company, engaged D. Brooks and Associates CPA's, P.A. as their PCAOB registered certified public auditing firm.
As BSEM transitions out of the start-up phase and into the growth stage, the corporate team will be shifting focus to driving future revenues from its pharmaceutical divisions starting this summer. A major key factor with uplisting to a fully reporting market is that it will allow the company to expand its shareholder base to "Wall Street" type investors as well as attracting institutional lenders with strategic portfolios.
BSEM plans to accompany the likes of Experian, Bombardier, Heineken and many more on the OTC QX market.
D. Brooks & Associates has completed the inventory audit of goods being sold through our eCommerce platforms, DrDavesBest.com and BioStemWellness.com. Next steps in the process involve document discovery for the Company's numerous acquisitions and business activities over the audit period. This process is expected to be completed sometime in Q2 2017 with the Uplisting to follow shortly after.
Henry "Chip" Van Vurst, CEO of BioStem Technologies went on to say, "This has been our goal since inception and we are now ready to execute this process. Uplisting to the OTCQX will allow the Company to build market awareness, establish enhanced trust and confidence with investors, investment banks and fund managers alike."
To find out more about BioStem Technologies please click the following link: www.506craise.com.
About D. Brooks and Associates CPA's, P.A. Headquartered in West Palm Beach, Florida, D. Brooks and Associates CPA's, P.A. is a PCAOB registered certified public accounting firm that offers clients professional and courteous attention while delivering practical value in addressing their needs. We have extensive experience in assisting clients with highly complex issues as well as day to day operational needs. Our principals are native residents of South Florida and share a passion for helping businesses and individuals achieve success in financial matters.
The Firm's philosophy is to provide clients National level technical expertise through hands on relationships that emphasize understanding client issues, addressing them with appropriate urgency, and maintaining effective communications so as to maximize value delivered as a result of these relationships.
About BioStem Technologies, Inc. (OTC PINK: BSEM): BioStem Technologies, Inc. (OTC PINK: BSEM) is in the business of regenerative medicine and antiaging strategies throughout the United States, Europe, and Mexico. The Company's mission is to conquer the effects of biological aging (and related acute disease), and its strategy is to discover, develop, produce, and deliver the most effective stem cell and wellness products in the world. The Company is comprised of a diverse group of scientists, physicians, and industry visionaries who are creating innovative products for helping customers live their best, feel their best, and be their best. The company operates six strategic business units - BioStem Cell Therapy, BioStem Wellness, BioStem Pharmaceuticals, Qualified Pharma Ingredients, BioBlue Technologies, and BioStem International - providing a diversified line of products and services that include: clinical stem cell therapy, stem cell R&D, state-of-the-art laboratory services, pharmaceuticals, nutraceuticals, cosmeceuticals, API repackaging, and medical tourism.
Forward-Looking Statements: Except for statements of historical fact, the matters discussed in this press release are forward looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "future," "plan" or "planned," "expects," believe" or "projected." These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the company's control that may cause actual results to differ materially from stated expectations. These risk factors include, among others, limited operating history, difficulty in developing, exploiting and protecting proprietary technologies, intense competition and additional risks factors as discussed in reports filed by the company with OTC Markets.
Contact Information
BioStem Technologies, Inc.
?Phone: 954-380-8342 ?
Website: http://www.biostemtech.com ?
Email: info@biostemtech.com?
Twitter: @Biostemtech
Facebook: BioStem Technologies??
Investor Relations:? Andrew Van Vurst?
info@biostemtech.com?
954.380.8342
$BSEM BioStem Technologies, Inc. Announces Completion of 503b Pharmaceutical and Stem Cell Research Laboratory
Source: Marketwired
OAKLAND PARK, FL-(Marketwired - Mar 24, 2017) - BioStem Technologies, Inc. (OTC PINK: BSEM) ("BSEM" or "the company"), an emerging International BioTech company, celebrated the opening of its new laboratory and corporate offices with a ribbon cutting ceremony hosted by the BioStem Technologies executive team. BSEM's Founder and CEO, Henry Van Vurst, commented, "With the recent regulation changes we amended our original facility design to comply with FDA 503b regulations, which caused an extension to our timeline, but I couldn't be prouder of this new state-of-the-art facility. Cutting the ribbon with Mayor Lamar Fisher (City of Pompano Beach) was a very proud moment for the entire BSEM team, and it is a testament to how far we have come since the Company's inception in 2014."
The facility is a showcase of quality that will enable BSEM to leverage its vertical integration strategy in the Health, Wellness and Biotechnology sectors. The lab will serve as the Quality, R&D, and Pharmaceutical Manufacturing Laboratory, not only for the Company's in-house operations, but also for its contract formulation and contract manufacturing services. The Company is in the process of finalizing its certifications for the ISO 8, 7, and 5 suites, as well as validation of the cGMP and cGLP areas. Corporate operations are expected to move to the new facility in Q2 2017, while the operations of Qualified Pharma Ingredients, one of the company's subsidiaries, will remain at its current location in Oakland Park, Florida.
About BioStem Technologies, Inc. (OTC PINK: BSEM): BioStem Technologies, Inc. (OTC PINK: BSEM) is in the business of regenerative medicine and antiaging strategies throughout the United States, Europe, and Mexico. The Company's mission is to conquer the effects of biological aging (and related acute disease), and its strategy is to discover, develop, produce, and deliver the most effective stem cell and wellness products in the world. The Company is comprised of a diverse group of scientists, physicians, and industry visionaries who are creating innovative products for helping customers live their best, feel their best, and be their best. The company operates six strategic business units - BioStem Cell Therapy, BioStem Wellness, BioStem Pharmaceuticals, Qualified Pharma Ingredients, BioBlue, and BioStem International - providing a diversified line of products and services that include: clinical stem cell therapy, stem cell R&D, state-of-the-art laboratory services, pharmaceuticals, nutraceuticals, cosmeceuticals, API repackaging, and medical tourism.
Forward-Looking Statements: Except for statements of historical fact, the matters discussed in this press release are forward looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "future," "plan" or "planned," "expects," believe" or "projected." These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the company's control that may cause actual results to differ materially from stated expectations. These risk factors include, among others, limited operating history, difficulty in developing, exploiting and protecting proprietary technologies, intense competition and additional risks factors as discussed in reports filed by the company with OTC Markets.
BioStem Technologies, Inc.
?Phone: 954-380-8342
Website: http://www.biostemtech.com ?
Email: info@biostemtech.com?
Twitter: @Biostemtech?
Facebook: BioStem Technologies??
Investor Relations: Andrew Van Vurst? info@biostemtech.com
?954.380.8342
BioStem Technologies, Inc. Announces Completion of 503b Pharmaceutical and Stem Cell Research Laboratory
OAKLAND PARK, FL--(Marketwired - Mar 24, 2017) - BioStem Technologies, Inc. (OTC PINK: BSEM) ("BSEM" or "the company"), an emerging International BioTech company, celebrated the opening of its new laboratory and corporate offices with a ribbon cutting ceremony hosted by the BioStem Technologies executive team. BSEM's Founder and CEO, Henry Van Vurst, commented, "With the recent regulation changes we amended our original facility design to comply with FDA 503b regulations, which caused an extension to our timeline, but I couldn't be prouder of this new state-of-the-art facility. Cutting the ribbon with Mayor Lamar Fisher (City of Pompano Beach) was a very proud moment for the entire BSEM team, and it is a testament to how far we have come since the Company's inception in 2014."
The facility is a showcase of quality that will enable BSEM to leverage its vertical integration strategy in the Health, Wellness and Biotechnology sectors. The lab will serve as the Quality, R&D, and Pharmaceutical Manufacturing Laboratory, not only for the Company's in-house operations, but also for its contract formulation and contract manufacturing services. The Company is in the process of finalizing its certifications for the ISO 8, 7, and 5 suites, as well as validation of the cGMP and cGLP areas. Corporate operations are expected to move to the new facility in Q2 2017, while the operations of Qualified Pharma Ingredients, one of the company's subsidiaries, will remain at its current location in Oakland Park, Florida.
About BioStem Technologies, Inc. (OTC PINK: BSEM): BioStem Technologies, Inc. (OTC PINK: BSEM) is in the business of regenerative medicine and antiaging strategies throughout the United States, Europe, and Mexico. The Company's mission is to conquer the effects of biological aging (and related acute disease), and its strategy is to discover, develop, produce, and deliver the most effective stem cell and wellness products in the world. The Company is comprised of a diverse group of scientists, physicians, and industry visionaries who are creating innovative products for helping customers live their best, feel their best, and be their best. The company operates six strategic business units -- BioStem Cell Therapy, BioStem Wellness, BioStem Pharmaceuticals, Qualified Pharma Ingredients, BioBlue, and BioStem International -- providing a diversified line of products and services that include: clinical stem cell therapy, stem cell R&D, state-of-the-art laboratory services, pharmaceuticals, nutraceuticals, cosmeceuticals, API repackaging, and medical tourism.
Forward-Looking Statements: Except for statements of historical fact, the matters discussed in this press release are forward looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "future," "plan" or "planned," "expects," believe" or "projected." These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the company's control that may cause actual results to differ materially from stated expectations. These risk factors include, among others, limited operating history, difficulty in developing, exploiting and protecting proprietary technologies, intense competition and additional risks factors as discussed in reports filed by the company with OTC Markets.
BioStem Technologies, Inc. (OTC Pink: BSEM) Opens New Sudsidiary Qualified Pharma Ingredients, Inc.
OAKLAND PARK, FL--(Marketwired - Nov 18, 2016) - BioStem Technologies, Inc. (OTC PINK: BSEM) today announced the formation of Qualified Pharma Ingredients, Inc. (QPI), a subsidiary that will focus on supplying the highest quality Active Pharmaceutical Ingredients available. Qualified Pharma Ingredients has partnered with pharmaceutical sales and marketing experts for the development of this business unit. QPI has already received its FDA Establishment Registration and is now awaiting their State of Florida Department of Business and Professional Regulation (DBPR) inspection for Prescription Drug Repackager.
For over 2 years, BioStem Technologies (BSEM) has acquired numerous business units and formed five subsidiaries in the Health and Wellness sectors. QPI is BSEM's most recent venture, supplying Active Pharmaceutical Ingredients to the Pharmaceutical and Compounding industry with emphasis on superior quality and procurement systems. This is achieved through the acquisition of key team members from the pharmaceutical industry having over 40 years of combined manufacturing and quality control knowledge.
The recent issuance of updated federal guidance has suggested serious concerns about the state of the industry's compliance regarding manufacturing and quality systems for the API suppliers. Regulatory agencies will be paying close attention to the qualifications of API manufacturers, along with product tracking and tracibility from procurement to distribution, with serialization required in the Repackaging industry by 2018. Andrew VanVurst, BioStem Technologies COO stated, "Entering into the pharmaceutical market can be a tedious process, and with the new regulations coming into effect on quality, product traceablity, and control we have developed robust systems to meet and exceed future guidance standards. While other companies scramble to meet the rapidly changing industry, QPI has an advantage by exceeding any current FDA guidance or regulation from inception."
About BioStem Technologies, Inc. (OTC PINK: BSEM): BioStem Technologies, Inc. (OTC PINK: BSEM) is in the business of regenerative medicine and antiaging strategies throughout the United States, Europe, and Mexico. The Company's mission is to conquer the effects of biological aging (and related acute disease), and its strategy is to discover, develop, produce, and deliver the most effective stem cell and wellness products in the world. The Company is comprised of a diverse group of scientists, physicians, and industry visionaries who are creating innovative products for helping customers live their best, feel their best, and be their best. The company operates five strategic business units -- BioStem Cell Therapy, BioStem Wellness, BioStem Pharmaceuticals, Qualified Pharma Ingredients and BioStem International -- providing a diversified line of products and services that include: clinical stem cell therapy, stem cell R&D, state-of-the-art laboratory services, pharmaceuticals, nutraceuticals, cosmeceuticals, API Repackaging, and medical tourism.
Forward-Looking Statements: Except for statements of historical fact, the matters discussed in this press release are forward looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "future," "plan" or "planned," "expects," believe" or "projected." These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the company's control that may cause actual results to differ materially from stated expectations. These risk factors include, among others, limited operating history, difficulty in developing, exploiting and protecting proprietary technologies, intense competition and additional risks factors as discussed in reports filed by the company with OTC Markets.
BioStem Technologies, Inc. (OTC Pink: BSEM) Acquires Their First FDA Approved Branded Generic Drug (ANDA) -- Granisol® Oral Solution
OAKLAND PARK, FL--(Marketwired - Aug 22, 2016) - BioStem Technologies, Inc. (OTC PINK: BSEM) (the "Company" or "BioStem"), announced today that it has acquired its first FDA approved branded generic drug (ANDA), Granisol® Oral Solution ("Granisol"), an effective medicine for preventing nausea and vomiting associated with cancer chemotherapy and radiation treatments.
Henry Van Vurst, CEO of BioStem Technologies, commented, "As a surviving cancer patient myself, I know first-hand the uncomfortable feelings of nausea while undergoing chemotherapy. We are very excited to announce our acquisition of Granisol -- a drug that relieves a major pain point for patients during this time. We look forward to marketing it effectively and profitably, and helping cancer patients feel better while fighting a very difficult battle."
Granisol® Oral Solution is proven to be a highly effective anti-nauseant during initial and repeat courses of emetogenic cancer therapy, including high-dose cisplatin, total body irradiation, and fractionated abdominal radiation. Granisol® contains granisetron hydrochloride, an antiemetic (anti-nauseant) agent. The recommended adult dosage is 2 mg once daily, or 1 mg twice daily. In the 2 mg once-daily regimen, 10 mL of Granisol Oral Solution (2 teaspoonsful, equivalent to 2 mg of granisetron) are given up to 1 hour before chemotherapy. In the 1 mg twice-daily regimen, the first teaspoonful (5 mL) of Granisol Oral Solution is given up to 1 hour before chemotherapy, and the second teaspoonful (5 mL) of Granisol Oral Solution, 12 hours after the first. Either regimen is administered only on the day(s) chemotherapy is given.
About BioStem Technologies, Inc. (OTC PINK: BSEM): BioStem Technologies (OTC PINK: BSEM) is in the business of regenerative medicine and antiaging strategies throughout the United States, Europe, and Mexico. The Company's mission is to conquer the effects of biological aging (and related acute disease), and its strategy is to discover, develop, produce, and deliver the most effective stem cell and wellness products in the world. The Company is comprised of a diverse group of scientists, physicians, and industry visionaries who are creating innovative products for helping customers live their best, feel their best, and be their best. The company operates four strategic business units -- BioStem Cell Therapy, BioStem Wellness, BioStem Pharmaceuticals, and BioStem International -- providing a diversified line of products and services that include: clinical stem cell therapy, stem cell R&D, state-of-the-art laboratory services, pharmaceuticals, nutraceuticals, cosmeceuticals, API Repackaging, and medical tourism.
Forward-Looking Statements: Except for statements of historical fact, the matters discussed in this press release are forward looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "future," "plan" or "planned," "expects," believe" or "projected." These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the company's control that may cause actual results to differ materially from stated expectations. These risk factors include, among others, limited operating history, difficulty in developing, exploiting and protecting proprietary technologies, intense competition and additional risks factors as discussed in reports filed by the company with OTC Markets.
BioStem Technologies, Inc. (OTC Pink: BSEM) Begins Construction of New Laboratory Facility
OAKLAND PARK, FL--(Marketwired - Jul 13, 2016) - BioStem Technologies, Inc. (OTC PINK: BSEM) (the "Company" or "BioStem") announced today the commencement of construction of the Company's new pharmaceutical grade laboratory facility. Biostem's pharmaceutical and nutraceutical operations have expanded rapidly since the change of control in late 2014, and the Company has revised its original plans for the facility to include less office space and more 'small batch' manufacturing rooms and general laboratory space.
The new, state-of-the-art facility will house multiple general labs, clean rooms, and small batch manufacturing rooms to support production and development of pharmaceutical, nutraceutical and cell based products. The facility will also be open for industrial and educational tours as a way of furthering BioStem's integrated mission of science, education and exhibition of the vast array of opportunities and benefits that are available to mankind through stem cell and nutritional products.
"This facility will give our scientists and researchers the laboratory resources they need to rapidly develop new products. We're looking forward to streamlining our developmentment and manufacturing processes, and to having the ability to test efficacy of these compounds in-house" said Andrew Van Vurst, COO of BioStem Technologies.
About BioStem Technologies, Inc. (OTC PINK: BSEM): BioStem Technologies (OTC PINK: BSEM) is in the business of regenerative medicine and antiaging strategies throughout the United States, Europe, and Mexico. The Company's mission is to conquer the effects of biological aging (and related acute disease), and its strategy is to discover, develop, produce, and deliver the most effective stem cell and wellness products in the world. The Company is comprised of a diverse group of scientists, physicians, and industry visionaries who are creating innovative products for helping customers live their best, feel their best, and be their best. The company operates four strategic business units - BioStem Cell Therapy, BioStem Wellness, BioStem Pharmaceuticals, and BioStem International - providing a diversified line of products and services that include: clinical stem cell therapy, stem cell R&D, state-of-the-art laboratory services, pharmaceuticals, nutraceuticals, cosmeceuticals, API Repackaging, and medical tourism.
Forward-Looking Statements: Except for statements of historical fact, the matters discussed in this press release are forward looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "future," "plan" or "planned," "expects," believe" or "projected." These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the company's control that may cause actual results to differ materially from stated expectations. These risk factors include, among others, limited operating history, difficulty in developing, exploiting and protecting proprietary technologies, intense competition and additional risks factors as discussed in reports filed by the company with OTC Markets.
BioStem Technologies, Inc. (OTC: BSEM) Announces Issuance of FDA Drug Establishment Registration Number and FDA Labeler Code to Wholly Owned Subsidiary BioStem Pharmaceuticals, Inc.
OAKLAND PARK, FL--(Marketwired - Jun 2, 2016) -
BioStem Technologies, Inc. ("BioStem" or the "Company") (OTC PINK: BSEM) announced today that the FDA has accepted and issued BioStem Pharmaceuticals, Inc., a wholly owned subsidiary of the Company, its FDA Drug Establishment Registration Number and Labeler Code for Manufacturing and Repackaging of pharmaceutical products.
BioStem Pharmaceuticals is a pharmaceutical distribution and manufacturing company that is focused on the redistribution of Active Pharmaceutical Ingredients as well as development and approval of New Drug Applications. The FDA Establishment Registration and Labeler Code allows BioStem Pharmaceuticals to manufacture and distribute pharmaceuticals products in the United States.
The Office of Compliance, Immediate Office oversees the electronic Drug Registration and Listing System, a key component of the Food and Drug Administration's ability to monitor drug safety. Section 510 of the Federal Food, Drug, and Cosmetic Act requires firms that manufacture, prepare, propagate, compound, or process drugs in the U.S. or that are offered for import into the U.S. to register with the FDA. These domestic and foreign firms must at the time of registration, list all drugs manufactured, prepared, propagated, compounded, or processed for commercial distribution in the U.S.
Joe Esposito, President of BioStem Pharmaceuticals, went on to say, "We are very excited to have this process completed. This now gives us the ability to move forward with the development and manufacturing of strategically chosen products that have been mapped out in our business plan."
About BioStem Technologies, Inc. (OTC PINK: BSEM): BioStem Technologies (OTC PINK: BSEM) is in the business of regenerative medicine and antiaging strategies throughout the United States, Europe, and Mexico. The Company's mission is to conquer the effects of biological aging (and related acute disease), and its strategy is to discover, develop, produce, and deliver the most effective stem cell and wellness products in the world. The Company is comprised of a diverse group of scientists, physicians, and industry visionaries who are creating innovative products for helping customers live their best, feel their best, and be their best. The company operates four strategic business units - BioStem Cell Therapy, BioStem Wellness, BioStem Pharmaceuticals, and BioStem International - providing a diversified line of products and services that include: clinical stem cell therapy, stem cell R&D, state-of-the-art laboratory services, pharmaceuticals, nutraceuticals, cosmeceuticals, API Repackaging, and medical tourism.
Forward-Looking Statements Except for statements of historical fact, the matters discussed in this press release are forward looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "future," "plan" or "planned," "expects," believe" or "projected." These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the company's control that may cause actual results to differ materially from stated expectations. These risk factors include, among others, limited operating history, difficulty in developing, exploiting and protecting proprietary technologies, intense competition and additional risks factors as discussed in reports filed by the company with OTC Markets.
BioStem Technologies, Inc. (OTC: BSEM) Appoints David Wolfe and Dr. Michael Beckwith to Its Advisory Board
OAKLAND PARK, FL--(Marketwired - May 27, 2016) - BioStem Technologies, Inc. ("BioStem" or the "Company") (OTC PINK: BSEM) today announced the appointment of David Wolfe and Rev. Michael Bernard Beckwith to its Advisory Board. The Advisory Board of the Company provides advice and guidance to the Board of Directors of the Company, but Advisory Board members are not Directors of the Corporation. Mr. Wolfe and Dr. Beckwith are both well-known opinion leaders in their respective fields.
David "Avocado" Wolfe is a leading educator and 22-year promoter of superfoods that impact longevity, and he has consulted for the world's top CEOs, ambassadors, celebrities, athletes, artists (and Moms, of course). He is the co-developer and spokesperson for the NUTRiBULLET™, which is now the nation's #1 selling kitchen appliance. He is also the co-founder of TheBestDayEver.com online health magazine and the Founder and President of the non-profit The Fruit Tree Planting Foundation charity (www.ftpf.org), which has a mission to plant 18 billion fruit, nut, and medicinal trees around the world.
Reverend Michael Beckwith has authored eight books, produced three movies, and co-authored 120 songs. Dr. Beckwith's notoriety climbed through the production of the very successful film The Secret (2006). He was a regular guest of the Oprah Winfrey and Larry King television programs, and his weekly Friday afternoon radio program on the Los Angeles station, KPFK, is hugely popular. Dr. Beckwith's humanitarian efforts have attracted numerous awards including the 1999 Humanitarian Award from the National Conference for Compassion and Justice, the 2001 Gandhi-King-Ikeda Award from Morehouse College, the 2004 Africa Achievement Peace Award, the 2006 Black Aids Institute Hero Award; and in 2009, the Ebony Magazine's 150 Award. In 1999 he was inducted into the Assembly of the Parliament of the World's Religions.
Henry Van Vurst, BioStem's CEO went on to say, "We could not be more pleased to have Michael Beckwith and David Wolfe joining the team. I strongly believe that the addition of these world-renowned thought leaders will further insure BioStem Technologies' mission of being the Global Leader in Anti-Aging and Regenerative Medicine. Both of these individuals bring a sense of enthusiasm and depth of understanding for the overall wellness of people that is imperative at BioStem Technologies."
About BioStem Technologies, Inc. (OTC PINK: BSEM): BioStem Technologies (OTC PINK: BSEM) is in the business of regenerative medicine and antiaging strategies throughout the United States, Europe, and Mexico. The Company's mission is to conquer the effects of biological aging (and related acute disease), and its strategy is to discover, develop, produce, and deliver the most effective stem cell and wellness products in the world. The Company is comprised of a diverse group of scientists, physicians, and industry visionaries who are creating innovative products for helping customers live their best, feel their best, and be their best. The company operates four strategic business units - BioStem Cell Therapy, BioStem Wellness, BioStem Pharmaceuticals, and BioStem International - providing a diversified line of products and services that include: clinical stem cell therapy, stem cell R&D, state-of-the-art laboratory services, pharmaceuticals, nutraceuticals, cosmeceuticals, API Repackaging, and medical tourism.
Forward-Looking Statements Except for statements of historical fact, the matters discussed in this press release are forward looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "future," "plan" or "planned," "expects," believe" or "projected." These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the company's control that may cause actual results to differ materially from stated expectations. These risk factors include, among others, limited operating history, difficulty in developing, exploiting and protecting proprietary technologies, intense competition and additional risks factors as discussed in reports filed by the company with OTC Markets.
BioStem Technologies, Inc. (OTC PINK: BSEM) Completes Capital Restructuring Initiatives
OAKLAND PARK, FL--(Marketwired - May 26, 2016) - BioStem Technologies, Inc. (OTC PINK: BSEM) -- the Company amended the Certificates of Designation for its Series A-1 Convertible Preferred Shares and its Series B-1 Convertible Preferred Shares.
The Certificate of Designation for the Series A-1 Convertible Preferred Shares was amended (i) to reduce the number of authorized Series A-1 Convertible Preferred Shares from 500,000 to 300; (ii) to provide that each Series A-1 Convertible Preferred Share will have 2 million votes on any matter submitted to the shareholders of the Company; (iii) to provide that each Series A-1 Convertible Preferred Share will convert into one share of common stock of the Company.
The Certificate of Designation for the Series B-1 Convertible Preferred Shares was amended to provide that each Series B-1 Convertible Preferred Share will convert into 6 shares of common stock of the Company.
The amendments were approved by the Board of Directors of the Company and by the holders of the Series A-1 Convertible Preferred Shares and the Series B-1 Convertible Preferred Shares, on May 19, 2016.
Prior to these new designations, the holders of the preferred stock held a non-dilutable 55% equity stake (Preferred A-1), and a non-dilutable 15% equity stake (Preferred B-1) which combined, represented a non-dilutable 70% stake in BioStem Technologies, whereas the percentage following the amendments to the designations is now 46.6% on a fully diluted basis. Based on our current organizational documents, with any new stock offering going forward, all of our common and preferred stock shareholders will be diluted pari passu, on a fair and equitable basis. We believe that increasing shareholder equity and eliminating the possibility of unequal dilution will be viewed more favorably by the investment community.
About BioStem Technologies, Inc. (OTC PINK: BSEM): BioStem Technologies (OTC PINK: BSEM) is in the business of regenerative medicine and antiaging strategies throughout the United States, Europe, and Mexico. The Company's mission is to conquer the effects of biological aging (and related acute disease), and its strategy is to discover, develop, produce, and deliver the most effective stem cell and wellness products in the world. The Company is comprised of a diverse group of scientists, physicians, and industry visionaries who are creating innovative products for helping customers live their best, feel their best, and be their best. The company operates four strategic business units -- BioStem Cell Therapy, BioStem Wellness, BioStem Pharmaceuticals, and BioStem International -- providing a diversified line of products and services that include: clinical stem cell therapy, stem cell R&D, state-of-the-art laboratory services, pharmaceuticals, nutraceuticals, cosmeceuticals, API Repackaging, and medical tourism.
Forward-Looking Statements Except for statements of historical fact, the matters discussed in this press release are forward looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "future," "plan" or "planned," "expects," believe" or "projected." These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the company's control that may cause actual results to differ materially from stated expectations. These risk factors include, among others, limited operating history, difficulty in developing, exploiting and protecting proprietary technologies, intense competition and additional risks factors as discussed in reports filed by the company with OTC Markets.
BioStem Technologies, Inc. (OTC Pink: BSEM) Acquires TEN® Health Behavior Change Platform
OAKLAND PARK, FL--(Marketwired - May 25, 2016) - BioStem Technologies, Inc. (OTC PINK: BSEM) today announced it has acquired, through its wholly owned subsidiary, the TEN® Health Behavior Change Platform and its associated patents, source code, website, and currently functioning mobile applications from Elencee, Inc. ("Elencee") on May 18, 2016 for 50,000 shares of restricted common stock of BSEM. The acquisition was completed pursuant to an asset purchase agreement (the "APA") entered into between BioStem Wellness, Inc. ("Wellness"), a wholly owned subsidiary of BSEM, and Elencee on May 18, 2016, and the acquisition was closed the same day.
For a period of 12 months, Elencee may not sell, assign, pledge, hypothecate, transfer or convey the BSEM shares to any third party without the express written consent of Wellness.
In addition to the payment of the shares, BSEM has executed a Royalty Agreement with Elencee which provides Elencee with an ongoing royalty payment, and also a payment in the event of a sale of the assets acquired by BSEM under the asset purchase agreement. Pursuant to the Royalty Agreement, Elencee will receive a 10% royalty in perpetuity on the adjusted gross profit earned on the acquired assets, and BSEM granted back to Elencee a right to use certain of the acquired assets for certain limited purposes related to the development of a computer game for children to educate them on healthy eating habits and certain related matters. BSEM has a right of first refusal under the Royalty Agreement to market the product if and when it is developed.
In addition, under the Royalty Agreement, if any products covered by the Royalty Agreement (including the intellectual property related thereto) are sold by BSEM to a bona-fide third party within three years of the closing of the acquisition, Elencee will receive 50% of the sale proceeds, with that percentage dropping to 25% for any sale between three years and five years after the closing of the acquisition, and to 10% for any sale more than five years after the closing of the acquisition.
The APA contains customary representations and warranties of the parties and covenants customary for agreements of this nature. The APA also contains indemnification obligations customary for agreements of this nature.
A technology platform, TEN is an intuitive personalized system that teaches people how to be healthier. The program promotes food and ingredient servings and health behaviors which decrease disease risk and increase life expectancy. Users whose goal is to lose weight can choose the personalized healthy weight loss program.
Traditional health and weight loss programs have a limited view on what is "healthy" by being calorie-focused. Only looking at calories doesn't teach people what foods and behaviors to change in order to be healthier and lose weight. That is why most people gain their weight back when they finish a calorie-focused program. In fact, calorie-focused programs reinforce bad behaviors like avoidance of healthy fats.
The TEN Platform (available at www.beTEN.com), includes a patented system promoting moderation, which departs from traditional "all or none" programs. This approach is more realistic for people who want to incorporate healthier habits within their day, without going to extremes. Extremes are short-lived and can be damaging, often having a negative effect.
BioStem Technologies, Inc.'s strategic acquisition of the TEN platform expands our product line and continues to build our ability to offer people access to our expansive health, wellness and anti-aging programs, and to our products online and via mobile apps.
About BioStem Technologies, Inc. (OTC PINK: BSEM): BioStem Technologies, Inc. is engaged in the advancement of regenerative medicine and antiaging strategies throughout the United States, Europe and Mexico. Our goal is to deliver the highest standard wellness and stem cell products that are backed by science. Through scientific studies, we seek to become a world leader in the wellness arena. This will be accomplished by using high quality nutraceuticals and stem cells. Our state-of-the-art laboratory is the first significant step in our quest to introduce the world and our shareholders to our dedication to you and your well-being.
Mission Statement - BioStem Technologies is a global leader in anti-aging and regenerative medicine. Our focus is to advance quality of life, health span, and wellness.
Vision Statement - BioStem Technologies is comprised of a group of scientists, physicians, and visionaries creating the possibility of living life to its fullest. Our products and strategies are dedicated to helping our customers live their best, feel their best, and be their best.
Forward-Looking Statements: Except for statements of historical fact, the matters discussed in this press release are forward looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "future," "plan" or "planned," "expects," believe" or "projected." These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the company's control that may cause actual results to differ materially from stated expectations. These risk factors include, among others, limited operating history, difficulty in developing, exploiting and protecting proprietary technologies, intense competition and additional risks factors as discussed in reports filed by the company with OTC Markets.
CONTACT INFORMATION
Contact:
BioStem Technologies, Inc.
Phone: 954-380-8342
Website: http://www.biostemtech.com
Email: info@biostemtech.com
Twitter: @Biostemtech
Facebook: BioStem Technologies
I stopped by new labs being built in Fort Lauderdale, state of the art facility. Wouldn't be surprised to see a billion dollar market cap on this stock one day. Big things about to happen STRONG BUY AT $10 all the way up to $15!!!!
MUST READ - 100% to 1000% potential So far this company has had news every month except SEPTEMBER just like in MAY 2016.
Last time there was double news was in MARCH and then nothing in APRIL.
The stock went from 8 to 16 at the end of MAY. In MAY it had two news articles that came out.
FEB 1
FEB 24
MAR 16
MAR 18
APRIL - NOTHING
MAY 25 (STOCK DOUBLED)
MAY 26
JUN 2
JUL 13
AUG 16
AUG 22
SEPT - NOTHING
OCT - ??? STOCK DOUBLE AGAIN, previous year it went 1000%
If history repeats it looks like something is about to happen here. RSI is low, meaning over sold just like around MARCH and now with the new drug they acquired. This company could see easily 100% gain in the next month or so.
If things are going well this could be a unicorn, now under the management of Doctors and specialist who are well known and with reputations. It looks like it was sold off to this group and they cleaned it up about a year ago and might be up to something big.
In November 2015 almost a year ago the stock went from 2 to 22 in a month. Let see where this does in the next 30 to 90 days.
I thought I share what I see, hopefully you can ride the wave to.
Chart Here
http://stockcharts.com/h-sc/ui?s=BSEM&p=D&yr=1&mn=0&dy=0&id=p92114066573
$BSEM BioStem Technologies, Inc. (OTC Pink: BSEM) Acquires Their First FDA Approved Branded Generic Drug (ANDA) - Granisol(R) Oral...
Source: Marketwired
BioStem Technologies, Inc. (OTC Pink: BSEM) Acquires Their First FDA Approved Branded Generic Drug (ANDA) - Granisol(R) Oral Solution
OAKLAND PARK, FL-(Marketwired - Aug 22, 2016) - BioStem Technologies, Inc. (OTC PINK: BSEM) (the "Company" or "BioStem"), announced today that it has acquired its first FDA approved branded generic drug (ANDA), Granisol Oral Solution ("Granisol"), an effective medicine for preventing nausea and vomiting associated with cancer chemotherapy and radiation treatments.
Henry Van Vurst, CEO of BioStem Technologies, commented, "As a surviving cancer patient myself, I know first-hand the uncomfortable feelings of nausea while undergoing chemotherapy. We are very excited to announce our acquisition of Granisol - a drug that relieves a major pain point for patients during this time. We look forward to marketing it effectively and profitably, and helping cancer patients feel better while fighting a very difficult battle."
Granisol Oral Solution is proven to be a highly effective anti-nauseant during initial and repeat courses of emetogenic cancer therapy, including high-dose cisplatin, total body irradiation, and fractionated abdominal radiation. Granisol contains granisetron hydrochloride, an antiemetic (anti-nauseant) agent. The recommended adult dosage is 2 mg once daily, or 1 mg twice daily. In the 2 mg once-daily regimen, 10 mL of Granisol Oral Solution (2 teaspoonsful, equivalent to 2 mg of granisetron) are given up to 1 hour before chemotherapy. In the 1 mg twice-daily regimen, the first teaspoonful (5 mL) of Granisol Oral Solution is given up to 1 hour before chemotherapy, and the second teaspoonful (5 mL) of Granisol Oral Solution, 12 hours after the first. Either regimen is administered only on the day(s) chemotherapy is given.
About BioStem Technologies, Inc. (OTC PINK: BSEM): BioStem Technologies (OTC PINK: BSEM) is in the business of regenerative medicine and antiaging strategies throughout the United States, Europe, and Mexico. The Company's mission is to conquer the effects of biological aging (and related acute disease), and its strategy is to discover, develop, produce, and deliver the most effective stem cell and wellness products in the world. The Company is comprised of a diverse group of scientists, physicians, and industry visionaries who are creating innovative products for helping customers live their best, feel their best, and be their best. The company operates four strategic business units - BioStem Cell Therapy, BioStem Wellness, BioStem Pharmaceuticals, and BioStem International - providing a diversified line of products and services that include: clinical stem cell therapy, stem cell R&D, state-of-the-art laboratory services, pharmaceuticals, nutraceuticals, cosmeceuticals, API Repackaging, and medical tourism.
Forward-Looking Statements: Except for statements of historical fact, the matters discussed in this press release are forward looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "future," "plan" or "planned," "expects," believe" or "projected." These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the company's control that may cause actual results to differ materially from stated expectations. These risk factors include, among others, limited operating history, difficulty in developing, exploiting and protecting proprietary technologies, intense competition and additional risks factors as discussed in reports filed by the company with OTC Markets.
Contact Information
BioStem Technologies, Inc.:
Phone: 954-380-8342
Website: http://www.biostemtech.com
Email: info@biostemtech.com
Twitter: @Biostemtech
Facebook: BioStem Technologies
Investor Relations:
Howard Gostfrand
info@amcapventures.com
305.918.7000
This company has never had a dividend. It looks like today they created an award previously unknown to the world before their fluff release to dump shares into.
You would think that for such a prestigious award there would have been mention of at least 1 prior recipient but NOTHING anywhere on the world wide web.
Does this company has been raising its dividend every year?
$BSEM Biostem Technologies, Inc. (OTC: BSEM) Signs 98-Acre Land Acquisition Contract in Iceland
Source: Marketwired
Biostem Technologies, Inc. (OTC: BSEM) Signs 98-Acre Land Acquisition Contract in Iceland
OAKLAND PARK, FL-(Marketwired - Feb 24, 2016) - Biostem Technologies, Inc. (OTC PINK: BSEM) - Biostem Technologies is pleased to announce executed contract for the purchase of 98 acres of waterfront property for plans to build a rejuvenation spa resort, to include stem cell treatments provided by Biostem Technologies. The property is situated in Reykjavik, Kjalarneshreppur and is approximately a 20-minute drive from the city centre. The signing signifies momentum toward developing "Nesvik" into a forward looking, luxurious and desirable location.
The ISK 145,000,000 (Approx. $1.12 mil USD) purchase agreement from Pera ehf, a company registered in Iceland enables the Biostem Technologies to move ahead with plans to expand into European markets. This expansion is expected to help position Biostem Technologies for continued diversification and economic development opportunities that will benefit the company and shareholders alike.
"The purchase agreement of this parcel of land for future development is a significant step taken in Biostem's commitment to building our international brand and positioning the company and shareholders for future prosperity," Jason Matuszewski, President and Chief Executive Officer, said.
Iceland is known around the world for its natural magnificence, geothermal power, and has become a booming tourism destination. The tourism industry has been growing drastically over recent years in Iceland, "Revenue from foreign tourists amounted to ISK 158,5 billion in 2014, i.e. ISK 27 billion more than in 2013. This represents a year-on-year increase of some 20%," Statistics Iceland.
Biostem Technologies is currently in negotiations with a "green" property development firm out of California for the development of the projected 100+ room facility. The Company believes that as Iceland is one of the fastest growing tourisms destinations in the world, and a central location between the Eastern US and Europe, this location will provide a perfect location to expand Biostem's business model for cellular treatments. We look forward to aiding in the stimulation of Iceland's local and national economy through providing jobs to natives and attracting tourism.
Renovations for the two existing buildings on the property are underway and should be completed by end of Q1.
Statistics Iceland Source:
http://www.ferdamalastofa.is/static/files/ferdamalastofa/Frettamyndir/2015/mai/tourism-in-iceland-in-figures_15.pdf
About Biostem Technologies, Inc. (BSEM):
BioStem Technologies (BSEM) is engaged in the advancement of regenerative medicine and antiaging strategies throughout the United States, Europe and Mexico. BSEM's goal is to deliver the highest standard wellness and stem cell products that are backed by science. Through scientific studies, we seek to become a world leader in the wellness arena. This will be accomplished by using high quality nutraceuticals and stem cells. Our state of the art laboratory is the first significant step in our quest to introduce the world and our shareholders our dedication to you and your well-being.
Mission Statement- Biostem Technologies is a Global Leader in Anti-Aging research. We are focused on advancing your quality of life, health span and wellness.
Vision Statement- Biostem Technologies is a group of scientists, physicians, and visionaries creating the possibility of living life to its fullest. Our products and strategies are dedicated to helping you live your best, feel your best, and be your best.
Forward-Looking Statements Except for statements of historical fact, the matters discussed in this press release are forward looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "future," "plan" or "planned," "expects," believe" or "projected." These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the company's control that may cause actual results to differ materially from stated expectations. These risk factors include, among others, limited operating history, difficulty in developing, exploiting and protecting proprietary technologies, intense competition and additional risks factors as discussed in reports filed by the company with OTC Markets.
Contact:
Biostem Technologies, Inc.
Phone: 954-380-8342
Website: http://www.biostemtech.com
Email: info@biostemtech.com
Twitter: @Biostemtech
Facebook: Biostem Technologies
$BSEM Biostem Technologies, Inc. (OTC: BSEM) Announces the Appointment of Dr. Dave Woynarowski as Chief Medical Officer
Source: Marketwired
Biostem Technologies, Inc. (OTC: BSEM) Announces the Appointment of Dr. Dave Woynarowski as Chief Medical Officer
OAKLAND PARK, FL-(Marketwired - Feb 1, 2016) - Dr. Dave Woynarowski was appointed Chief Medical Officer of Biostem Technologies, Inc. (OTC PINK: BSEM) effective immediately. Dr. Woynarowski received his medical degree from Temple University, and served as chief resident in his Internal Medicine Training program. He went on to become part of the resident education system, and twice receiving the prestigious Residents Teaching Award from his students and residents. He holds a Master's Degree in Physiology, and was a Certified Personal Trainer during his early medical career. He also served as Adjunct Professor to Hershey School of Medicine.
Dr. Woynarowski or more simply "Dr. Dave" as he is known to his patients has a background in Internal Medicine, and has been board certified in that discipline. He holds the A4M Anti-Aging medicine certification and was one of the first 30 physicians in the world to attain the AMA's certificate in Age Management Medicine. After practicing Internal Medicine for 15 years and Anti-Aging Medicine for 4 years he founded Dr. Dave's Best Nutraceuticals company in 2002 to fill the void in doctor designed nutraceuticals.
That company was acquired in November 2015 by Biostem Technologies, Inc. and Dr. Dave continues to direct its main functions including research and design.
Dr. Dave is also recognized as a worldwide expert on Telomeres and Telomerase. He has lectured on the topic multiple times to such groups as the A4M and AMMG.
In 2010 he wrote the first text book on Telomere biology for the non-scientist with co authors Dr. Mike Fossel and Greta Blackburn. Currently he is working on a second book which will include his expertise on other age related topics including stem cells and gene therapy.
On his transition to Biostem Technologies, Dr. Dave says, "This is actually a manifestation of a long term dream of mine. I have been working on developing a premier anti-aging team consisting of scientists, researchers, and entrepreneurs who are as dedicated to solving aging as I am. With that team now in place, I am excited to begin pursuing ideas that have been on hold for so long. We look forward to our ideas manifesting themselves into products and services that will help more people sooner!"
About Biostem Technologies, Inc. (BSEM):
Biostem Technologies (BSEM) is engaged in the advancement of regenerative medicine and anti-aging strategies throughout the United States, Europe, and Latin America. BSEM's goal is to deliver the highest standard wellness and stem cell products that are backed by science. Through scientific studies, we seek to become a world leader in the wellness arena. This will be accomplished by using the high quality nutraceuticals and stem cells. Our quest is to introduce the world, and our shareholders to our dedication to you and your well-being.
Mission Statement- Biostem Technologies is a Global Leader in Anti-Aging research. We are focused on advancing your quality of life, health span, and wellness.
Vision Statement- Biostem Technologies is a group of scientists, physicians, and visionaries creating the possibility of living life to its fullest. Our products and strategies are dedicated to helping you live your best, feel your best, and be your best.
Forward-Looking Statements
Except for statements of historical fact, the matters discussed in this press release are forward looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "future," "plan" or "planned," "expects," "believe" or "projected." These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the company's control that may cause actual results to differ materially from stated expectations. These risk factors include, among others, limited operating history, difficulty in developing, exploiting and protecting proprietary technologies, intense competition and additional risks factors as discussed in reports filed by the company with OTC Markets.
Contact Information
Contact:
Biostem Technologies, Inc.
Phone: 954-380-8342
Website: http://www.biostemtech.com
Email: info@biostemtech.com
Twitter: @biostemtech
Facebook: Biostem Technologies
$BSEM Biostem Technologies Completes Test-O-Shave Product Line Acquisition
Source: InvestorsHub NewsWire
Biostem Technologies Completes Test-O-Shave Product Line Acquisition
Oakland Park, FL -- December 11, 2015 -- InvestorsHub NewsWire -- (OTC: BSEM), Biostem Technologies, Inc. is pleased to announce the acquisition of another product line. Biostem Technologies (BSEM) acquired this asset by virtue of a stock exchange valued at, $155,500. Test-O-Shave is a product line focusing on providing natural grooming and hygiene products. In addition to the mens line of products, Test-O-Shave produces organic soaps, creams, oils, and a womens shave line in development. What sets this product line apart is its natural testosterone boosting ingredients, Pine Pollen and Tribulus.1 It has been shown that bisphenol A (PBA), preservatives and other artificial ingredients can naturally decrease your testosterone levels.1 Therefore; Test-O-Shave, with its all natural Pine Pollen and Tribulus may increase your natural testosterone levels.1 The Company will immediately re-brand this product line to its Bioshave brand to become the foundation of the Company's retail natural grooming and hygiene products.
Dr. Bryan Schuetz D.C., who developed Test-O-Shave stated: Commercially available shave soaps contain chemicals that may cause cancer and reduce normal testosterone levels. After learning of this I decided to form Test-O-Shave, a company that would produce only healthy, chemical free products for men and women to use each day. The first of these products is Test-O-Shave. After using this all natural formula for just a few days you will feel the difference from those old chemical shave creams that are just plain unhealthy for you. Get ready to feel what a real, natural product can do for you.
Jason Matuszewski, CEO of Biostem Technologies, commented: "We have continued to focus on identifying acquisitions as a means to grow and expand our capabilities, product offering and customer base. This last quarter, the company also decided to focus its resources in the upcoming year to penetrate the $5.4 billion cosmeceutical industry.
The acquisition of the Test-O-Shave product line, provides us with a jump-start into this market. It is our goal to complete the re-branding of Test-O-Shave to our Bioshave line and launch our consumer marketing program by the end of the first quarter of 2016.
With a successful product launch following the brand conversion, management anticipates this acquisition will account for an increase in revenues for Biostem Wellness in excess of 30%
For more information about Test-O-Shaves natural grooming and hygiene products please visit www.bioshaveshop.com
1: These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease.
About Biostem Technologies, Inc. (BSEM):
BioStem Technologies (BSEM) is engaged in the advancement of regenerative medicine and antiaging strategies throughout the United States, Europe and Mexico. BSEM's goal is to deliver the highest standard wellness and stem cell products that are backed by science. Through scientific studies, we seek to become a world leader in the wellness arena. This will be accomplished by using high quality nutraceuticals, cosmeceuticals, and stem cells. Our state of the art laboratory is the first significant step in our quest to introduce the world and our shareholders our dedication to you and your well-being.
Forward-Looking Statements Except for statements of historical fact, the matters discussed in this press release are forward looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "future," "plan" or "planned," "expects," believe or "projected." These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the company's control that may cause actual results to differ materially from stated expectations. These risk factors include, among others, limited operating history, difficulty in developing, exploiting and protecting proprietary technologies, intense competition and additional risks factors as discussed in reports filed by the company with OTC Markets.
Contact:
Biostem Technologies, Inc.
Phone: 954-380-8342
Website: http://www.biostemtech.com
Email: info@biostemtech.com
Twitter: @Biostemtech
Facebook: https://www.facebook.com/biostemtechnologies/
HOLY MACKEREL !!!!! WOW !!! Glad I'm in this game !!! Keep on going !!!
$$$$$$ loving the news and stock action.
Large spread between bid and ask. Looks like price headed down.
All sales and price is down. I am positive of this stock. I believe positive things are gonna happen and the pps Will reflect.
Is that a good thing or bad thing?
This stock is a needle in a haystack in my opinion. The needle has been found. News released. Things are setting up for a good ride imo.
Check out @biostemtech's Tweet: https://twitter.com/biostemtech/status/666264961656692737?s=09
$BSEM recent news/filings
bullish 8.15
stem cells and telomeres
anti-aging science
http://biostemtechnologies.com
## source: finance.yahoo.com
Sat, 17 Oct 2015 17:04:05 GMT ~ BIOSTEM TECHNOLOGIES INC Financials
read full: http://finance.yahoo.com/q/is?s=bsem
*********************************************************
Thu, 09 Apr 2015 12:51:00 GMT ~ BioStem Technologies Announces the Launch of our New Educational and Interactive Website
[Accesswire] - OAKLAND PARK, FL / ACCESSWIRE / April 9, 2015 / BioStem Technologies, Inc. (OTC PINK: BSEM) announces newly created educational and interactive website set to go live today, April 9, 2015. The launch of ...
read full: http://finance.yahoo.com/news/biostem-technologies-announces-launch-educational-125100482.html
*********************************************************
Thu, 09 Apr 2015 11:00:00 GMT ~ BioStem Technologies Announces the Launch of Our New Educational and Interactive Website
[Marketwired] - BioStem Technologies, Inc. announces newly created educational and interactive website set to go live today, April 9, 2015. The launch of the new website offers simple, fast, and user-friendly access to ...
read full: http://finance.yahoo.com/news/biostem-technologies-announces-launch-educational-110000401.html
*********************************************************
Tue, 27 Jan 2015 12:00:00 GMT ~ Biostem Technologies Announces 1:400 Reverse Stock Split
[Marketwired] - Biostem Technologies, Inc. , today announced that it has completed a 1-for-400 reverse split of its common stock, for all stockholders of record as of January 12th, 2015, effective as of the commencement ...
read full: http://finance.yahoo.com/news/biostem-technologies-announces-1-400-120000254.html
*********************************************************
Thu, 08 Jan 2015 13:00:00 GMT ~ BioStem Technologies (BSEM) Announces Retirement of 128,979,751 Shares of Common Stock and the Issuance of Amended Series B-1
[Accesswire] - Oakland Park, FL / ACCESSWIRE / January 8, 2015 / Biostem Technologies, Inc. (BSEM), announces that it has officially retired 128,979,751 shares of common stock. Furthermore, the company has amended its ...
read full: http://finance.yahoo.com/news/biostem-technologies-bsem-announces-retirement-130000382.html
*********************************************************
$BSEM charts
basic chart ## source: stockcharts.com
basic chart ## source: stockscores.com
big daily chart ## source: stockcharts.com
big weekly chart ## source: stockcharts.com
$BSEM company information
## source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/BSEM/company-info
Ticker: $BSEM
OTC Market Place: OTC Pink Current
CIK code: 0001634730
Company name: BioStem Technologies, Inc.
Company website: http://www.biostemtechnologies.com
Incorporated In: FL, USA
Business Description: BioStem Technologies (BSEM) is engaged in the advancement of regenerative medicine and anti-aging strategies throughout the United States, Europe and Mexico. BSEM's goal is to deliver the highest standard wellness and stem cell products that are backed by science. Through scientific studies, we seek to become a world leader in the wellness arena. This will be accomplished by using high quality nutraceuticals and stem cells. Our state of the art laboratory is the first significant step in our quest to introduce the world and our shareholders our dedication to you and your well-being.Less >>
$BSEM share structure
## source: otcmarkets.com
Market Value: $15,510,640 a/o Nov 13, 2015
Shares Outstanding: 1,903,146 a/o Jun 30, 2015
Float: 409,969 a/o Oct 14, 2015
Authorized Shares: 975,000,000 a/o Jun 30, 2015
Par Value: 0.001
$BSEM extra dd links
Company name: BioStem Technologies, Inc.
Company website: http://www.biostemtechnologies.com
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/BSEM/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/BSEM/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=BSEM+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=BSEM+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=BSEM+Industry
## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/BSEM/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/BSEM/news - http://finance.yahoo.com/q/h?s=BSEM+Headlines
## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/BSEM/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/BSEM/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/BSEM/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/BSEM/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/BSEM/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/BSEM/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/BSEM/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/BSEM/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=BSEM+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/BSEM
DTCC (dtcc.com): http://search2.dtcc.com/?q=BioStem+Technologies%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=BioStem+Technologies%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=BioStem+Technologies%2C+Inc.&x=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://www.biostemtechnologies.com
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://www.biostemtechnologies.com#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://www.biostemtechnologies.com
## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/BSEM/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/BSEM
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/BSEM/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/BSEM/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/BSEM/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001634730&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/BSEM/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/BSEM/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/BSEM/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/BSEM/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=BSEM&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=BSEM
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/BSEM/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=BSEM+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=BSEM+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=BSEM
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=BSEM
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=BSEM+Cash+Flow&annual
## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/BSEM/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=BSEM+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/BSEM.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=BSEM
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/BSEM/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/BSEM/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/BSEM/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/BSEM/insider-transactions
## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/BSEM
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/BSEM
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/BSEM:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=BSEM
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=BSEM
$BSEM DD Notes ~ http://www.ddnotesmaker.com/BSEM
Don't worry.......................................you will see "VOLUME" soon enough.
JMHO
GLTA
7X10
This stock needs some volume.
First down day since large percentage increase last Friday. No news. Price seems to increase on any sort of buying activity. Very low volume. I wonder where this stock could go with any type of volume. My only guess is That there would be a very large price increase. No social media activity or nothing happening with this stock.
Well , at least it still held its ground today in spite of the fact that there is no news around . Sure hope there was some news so we can decide what to do with this company . It would be nice .
Any sort of increase in volume and this is going to rocket imo. Mm need to raise price to get people to sell so they can sell to buyers. The mms have none to sell imo.
Whats going on?
Big News is coming for BSEM $$$
Hope you comeback and check in down the road...
Thanx but no need........................you will be the one who needs them....................not me. But I wish you the best of luck.
GLTA
JMHO
7X10
I will send you a box of tissues in 6 months....lol
Followers
|
200
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
48318
|
Created
|
01/18/07
|
Type
|
Free
|
Moderators |
BioStem Technologies, Inc. Appoints David Wolfe and Dr. Michael Beckwith to Its Advisory Board
BioStem Technologies, Inc. Completes Capital Restructuring Initiatives
BioStem Technologies, Inc. Acquires TEN® Health Behavior Change Platform
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |